8th Plenary Meeting EHDN 2014 Barcelona: 19-21 settembre 2014 – Report

Annarita Bentivoglio* - Marina Frontali** Si è appena concluso l’ottavo meeting plenario del Network Europeo per la Malattia di Huntington. Oltre 900 partecipanti: l’incontro più numeroso...

Fatal cellular malfunction identified in Huntington’s disease

Researchers believe they have learned how mutations in the gene that causes Huntington’s disease kill brain cells, a finding that could open new opportunities...

Vaccinex Provides Update of Potentially Pivotal SIGNAL Clinical Trial in Huntington’s...

Topline data anticipated in October 2020 as previously guided ROCHESTER, N.Y., July 07, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody...

Ohio State Conducts First Gene Therapy Clinical Trial For Huntington’s Disease

COLUMBUS, Ohio – In a worldwide first, surgeons at The Ohio State University Wexner Medical Center have treated two patients with Huntington’s disease using a novel...

Novel pathology could improve diagnosis and treatment of Huntington’s and other...

Bristol scientists have discovered a novel pathology that occurs in several human neurodegenerative diseases, including Huntington’s disease. The article, published in Brain Pathology, describes how SAFB1...

Changing jobs: converting other cell types into neurons

Because HD causes a loss of neurons in the brain, some researchers are exploring ways to replace them. Working with HD mice, scientists recently...

uniQure Announces First Two Patients Treated in Phase I/II Clinical Trial...

~ Milestone Marks the First-in-Human AAV Gene Therapy Trial for Huntington’s Disease ~ LEXINGTON, Mass. and AMSTERDAM, June 19, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE),...

High doses of ketamine can temporarily switch off the brain, say...

Researchers have identified two brain phenomena that may explain some of the side-effects of ketamine. Their measurements of the brain waves of sheep sedated by...

Antihistamines and similar drugs could slow down Huntington’s disease

Controlling dopamine signalling by targeting the histamine receptor has been shown to be a promising strategy for preventing the progression of Huntington’s disease in...

NEUROBIOLOGY OF DISEASE PUBLISHES ENCOURAGING PRECLINICAL RESULTS OF AFFIRIS’ ANTIBODY MAB...

Neurobiology of Disease publishes encouraging preclinical results of AFFiRiS’ antibody mAB C6-17 to treat Huntington’s disease Monoclonal antibody mAB C6-17 targeting human/mutant huntingtin protein...

Research highlights immune molecule’s complex role in Huntington’s disease

More than a decade before people with Huntington’s disease show symptoms, they can exhibit abnormally high levels of an immune-system molecule called interleukin-6 (IL-6),...

Optimal time to treat Huntington’s disease identified

The earliest brain changes due to Huntington’s disease can be detected 24 years before clinical symptoms show, according to a new UCL-led study The researchers...

RESEARCHERS DEVELOP NEW METHOD TO MAP CHOLESTEROL METABOLISM IN BRAIN

A team of researchers led by Swansea University have developed new technology to monitor cholesterol in brain tissue which could uncover its relation to...

HD Young Adult Study defines the sweet spot: symptom-free with measurable...

We know that HD-related changes can occur many years before symptom onset, but how early do those changes begin? A team of researchers set...

Teva Pharm gets approval in China for Huntington’s treatment

China has given the greenlight to Teva Pharmaceutical Industries’ Austedo treatment for Huntington’s disease, the company said on Monday. eva’s CEO Kare Schultz said the...

Fountain of youth: HTT protein repairs neurons by maintaining youthful state

Another clue about the normal function of the huntingtin protein; a team of scientists has recently found that huntingtin seems to play an important...

ReNeuron’s CTX cell line shows further potential

Newly published positive efficacy data in an accepted model of Huntington’s disease ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of...

Ionis and partner announce enrollment completion of global Phase 3 GENERATION...

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, today announced that its partner Roche, also known as Genentech in the United States, has completed enrollment for...

What does COVID-19 mean for Huntington’s disease families and HD research?

COVID-19 update: what does it mean for HD families, how does it impact HD research, and how has it changed the way science works? COVID-19,...

New molecule can reverse the Huntington’s disease mutation in lab models

A collaborative team of scientists from Canada and Japan have identified a small molecule which can change the CAG-repeat length in different lab models...

Huntington’s disease therapeutics conference 2020 – Day 3

HDBuzz reports from the annual Huntington’s disease therapeutics conference in Palm Springs Rachel and Sarah report from the Huntington’s Disease Therapeutics Conference - the biggest annual...

CHDI head scientist Pacifici: ‘hang on in the learning roller coaster...

With historic clinical trials now aiming for the first effective treatments for Huntington’s disease, affected individuals and their families need to clearly understand the...